Nivolumab的适应症是食管癌或胃食管连接部癌 此药物由Bristol-Myers Squibb Company/ Bristol-Myers Squibb Holdings Pharma, Ltd. Liability Company/ 百时美施贵宝(中国)投资有限公司生产并提出实验申请,[实验的目的] 1. 在已切除的食管或胃食管连接部癌受试者中比较nivolumab与安慰剂的OS 2. 在已切除的食管或胃...
doses are rounded to the nearest 20 mg, unless this exceeds 5% of the difference from the dose he or she would have received based on his or her weight (3 mg/kg), in which case, they increase to the higher dose (rounded up to the next 20 mg), up to a maximum of 240 mg. ...